Last reviewed · How we verify
NCT07006077
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Phase 2 trial testing Recombinant human IL-21-expressing oncolytic vaccinia virus injection in Advanced Pancreatic Cancer in 12 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Hangzhou Converd Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 29 May 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 5 March 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- Recombinant human IL-21-expressing oncolytic vaccinia virus injection — full drug profile →
Conditions studied
- Advanced Pancreatic Cancer — all drugs for Advanced Pancreatic Cancer →
Sponsor
Hangzhou Converd Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Fire in an Icy Desert: Oncolytic Virotherapy for Pancreatic Adenocarcinoma.
Rossetto A, Reale A. · · 2026 · PMID 42076160 · DOI 10.3390/pharmaceutics18040510 -
Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer.
Jin S, Zhang Y, Zhou Z, Zhang Y, et al · · 2026 · PMID 41970230 · DOI 10.1002/mco2.70725 -
Hydrogel Micro/Nanostructures for the Delivery of Oncolytic Viruses: Overcoming Limitations and Improving Efficacy.
Hsu CY, Jasim SA, Rizaev JA, Basunduwah TS, et al · · 2025 · PMID 41835051 · DOI 10.34172/apb.025.45842 -
Oncolytic viruses: A novel therapeutic approach for pancreatic cancer.
Esteves M, Matos AM, Cruz MT. · · 2025 · PMID 41211543 · DOI 10.1016/j.omton.2025.201069 -
Vaccinia Virus-A Swiss Army Knife Against Cancer.
Stawowczyk M, Ye Y, Chen NG. · · 2025 · PMID 40723208 · DOI 10.3390/cancers17142324
Verify or expand the search:
- PubMed search for NCT07006077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Recombinant human IL-21-expressing oncolytic vaccinia virus injection
Trials testing the same drug.
- NCT05914376 — Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors · Phase 1 · active not recruiting
Other recruiting trials for Advanced Pancreatic Cancer
Currently open trials in the same condition.
- NCT07416240 — Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer. · EARLY_PHASE1 · recruiting
- NCT06111274 — A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT06078787 — Olaparib in PALB2 Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT05916261 — Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer · EARLY_PHASE1 · recruiting
- NCT05380414 — Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients · NA · recruiting
Other Hangzhou Converd Co., Ltd. trials
Trials by the same sponsor.
- NCT05914376 — Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07006077 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hangzhou Converd Co., Ltd.
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07006077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing